Emmaus Life Sciences Q2 2026: Net Income Reaches $1.3M as Revenue Jumps 124%

summarizeSummary

Emmaus Life Sciences reported Q2 2026 net income of $1.3 million, a major improvement from a $1.1 million loss a year ago, driven by a new licensing deal with NeoImmuneTech. Revenue more than doubled to $6.3 million, but the company still has a going concern warning and a large working capital deficit.

check_boxKey Events · Earnings and Guidance · EMMA

• Q2 Revenue More Than Doubles

  Net revenues for Q2 2026 were $6.3 million, up 124% from $2.8 million in Q2 2025, primarily due to revenue recognition from the NeoImmuneTech license agreement.

• Swings to Net Income

  Net income was $1.3 million, or $0.02 per share, compared to a net loss of $1.1 million, or ($0.02) per share, in the same period last year.

• Operating Expenses Reduced

  Total operating expenses decreased 28% to $2.1 million from $3.0 million, driven by the transfer of the sales force to NeoImmuneTech.

• Cash Position Improves

  Cash and cash equivalents increased to $2.8 million at June 30, 2026, from $2.1 million at December 31, 2025.

auto_awesomeAnalysis · EMMA · Life Sciences

A dramatic turnaround unfolded in Q2 2026, with net revenues more than doubling to $6.3 million and the bottom line swinging to a net income of $1.3 million from a loss a year earlier. The improvement was driven by the new license agreement with NeoImmuneTech, which contributed upfront payment and royalty revenue, while operating expenses fell 28% due to the transfer of the sales force. However, the company still faces a going concern warning and a $60.1 million working capital deficit, as disclosed in the 10-Q filed the same day. The positive earnings surprise is notable, but the company's financial distress remains a significant risk.